JTT-551 is primarily investigated for its potential therapeutic applications in the treatment of type 2 diabetes. It functions as a selective peroxisome proliferator-activated receptor (PPAR) modulator, targeting PPARγ, which plays a key role in regulating glucose metabolism and insulin sensitivity. By modulating PPARγ activity, JTT-551 helps improve insulin resistance, a major factor in type 2 diabetes. Its selective action aims to provide the beneficial effects of PPARγ activation, such as improved glycemic control, while minimizing adverse effects like weight gain or fluid retention, which are commonly associated with other PPARγ agonists. This makes it a promising candidate for developing safer and more effective diabetes treatments. Research continues to explore its efficacy and safety in clinical settings.